Clinical trial
Study of the Adverse Events and Change in Disease State of Pediatric…
NCT05206357 · Genmab, Industry · Active, not recruiting
Key facts
| NCT number | NCT05206357 |
|---|---|
| Title | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab |
| Official title | A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
| Lead sponsor | Genmab, Industry |
| Collaborators | AbbVie Industry |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | Epcoritamab |
| Enrollment | 17 |
| Start date | Oct 4, 2022 |
| Primary completion | Nov 1, 2028 |
| Completion | Nov 1, 2028 |
| First posted | Jan 25, 2022 |
| Last update posted | Apr 8, 2025 |
| Countries | Australia, Belgium, Canada, Czechia, France, Germany, Israel, Italy, Japan, South Korea, Spain, Taiwan and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: